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While injection sclerotherapy has been accepted as the treatment of choice for acute variceal bleeding,
its role as a definitive long-term treatment modality has not yet been clearly defined. This paper will
critically analyse the current status of this technique, now widely used, and a comparison will be made
with conventional medical management. The review will be based on the 10 years’ Cape Town
experience and the published series on this subject. A long-term management strategy will also be
discussed.
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INTRODUCTION
Dissatisfaction with the results of management of bleeding oesophageal varices at
Groote Schuur Hospital in the seventies1’2 prompted the Liver Research Group in
Cape Town to launch prospective studies to evaluate the role of sclerotherapy both
during the acute bleeding episode and as an alternative definitive form of
long-term treatment4.
LONG-TERM SCLEROTHERAPY VERSUS MEDICAL TREATMENT
In the first long-term controlled study, repeated sclerotherapy (with the aim of
eradication of varices) was compared to a medical management regimen.
Emergency sclerotherapy was however instituted when balloon tamponade was
required to control recurrent bleeding episodes. Although recurrent acute variceal
bleeds were appreciably reduced by sclerotherapy, and eradication of varices was
usually possible, overall mortality was not reduced4’5.
Failure to improve survival was also reported in two further studies6’7 where the
control groups did not receive emergency salvage sclerotherapy for recurrent
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variceal bleeds. However, in Soderland’s and Korula’s studies, fewer deaths from
recurrent variceal bleeding occurred in patients who received sclerotherapy.
Improved survival was also calculated in the Los Angeles Study when patients
receiving shunt surgery were excluded from the survival analysis. The Kings
College and Copenhagen trials also showed a significantly improved long-term
survival associated with fewer recurrent variceal bleeds in the sclerotherapy group.
The difference in the latter study was, however, only evident 40 days after the index
bleed.
The differences in the various trials comparing sclerotherapy with medical
treatment have highlighted the difficulties in interpretation of treatment regimens
in such a complicated condition. There are many variables which could influence
the outcome including timing of therapy, entry criteria, aetiology and severity of
the underlying liver disease, management strategies, techniques of sclerotherapy
and continued alcohol abuse. The failure to show benefit with injection sclerother-
apy in the Cape Town study could be explained by the use of salvage emergency
sclerotherapy in the medically treated control group4’5. In the Kings College study
the entry of patients only after they had survived the initial period might have
introduced a bias8. Nevertheless, the Copenhagen study did show a clear long-term
benefit of sclerotherapy in terms of reduced recurrent variceal bleeding and related
mortality9.
On balance, current knowledge based on the results of controlled and uncon-
trolled studies would suggest that patients in whom varices are successfully
eradicated fare better than those who receive conventional medical therapy.
CAPE TOWN 10 YEARS’ EXPERIENCE
A recent review of our total experience in the long-term management of 245
patients who have bled from varices has again confirmed sclerotherapy as a viable
definitive form of treatment for the majority of patients1. Alcoholic cirrhosis was
the commonest aetiology (57%) and the Pugh-Childs risk gradings were A: 72
(40 portal vein thrombosis), B: 81, C: 78, unknown: 14. Flexible fibreoptic
endoscopy under sedation replaced rigid oesophagoscopy half-way through the
study period. A combined intra and paravariceal injection technique was employed
using ethanolamine oleate as sclerosant.
This study has confirmed both our own4’5 and others
6-9 previous finding that
varices can be eradicated in the majority of patients, but showed that this required
a median of five injection sclerotherapy sessions over a mean period of 9.25
months. Nevertheless the prognosis in patients in whom varices were eradicated
was good and the risk of rebleeding low (10.6%).
There remains, however, a hard core of patients who develop recurrent variceal
bleeds after their first admission. In this series 41 patients (17%) had no less than
119 variceal bleeding episodes during 81 subsequent admissions, and 53 per cent of
the episodes required the addition of balloon tamponade for control. While dealth
was directly attributed to bleeding in only 8 patients, it is conceivable that some of
the "liver failure" deaths could have been due to massive blood loss and transfu-
sion.
Although the complications of sclerotherapy were cumulative with time, only
few were life-threatening. There were 17 (7%) injection site leaks and all settled onLONG-TERM SCLEROTHERAPY 7
conservative treatment. However this resulted in treatment delays and some deaths
were due to recurrent bleeding and liver failure during such delays. Four oesopha-
geal ruptures after rigid oesophagoscopy were more serious and were associated
with two deaths. Most of the 52 per cent mortality of the 245 patients over the 10
year period was due to liver failure. The prognosis was predictably poor in Childs
C alcoholic cirrhotic patients but a continued analysis of the results of sclerotherapy
in patients with extrahepatic portal vein thrombosis confirmed the excellent results
of a previous communication from our unit and from others12.
TECHNIQUE
The rigid oesophagoscope, which ushered in the new era of enthusiasm for
sclerotherapy5’13’14 in the seventies, has now been superseded by the flexible
fibreoptic endoscope15. It has proved to be as effective as the rigid scope in one
controlled study
16 both in acute and long-term management. It is safer than the
rigid scope, does not require a general anaesthetic and most patients can be treated
more cost-effectively on an outpatient basis. Needless to say this is a major cost-
saving factor. Earlier reports advocated the use of an outer sheath
17 or some form
of balloon compressionTM, but simpler free-hand injection has become the most
widely used technique. However, the use of an outer sheath does seem to speed-up
eradication17’19 and should be considered in difficult cases. The novel endoscopic
ligation device2 seems promising and the results of controlled studies comparing
this with sclerotherapy are awaited with interest.
While most workers agree that the lower oesophagus is the most important site
for sclerosing varices, it remains uncertain whether the injection should be
intravariceal. To produce thrombosis of the varix, or paravariceal in the submucosal
plane to evoke mucosal and submucosal thickening. The intravariceal technique
has been used widely in Great Britain and the United States while most European
workers continue to use the submucosal technique. So far only one prospective
randomised trial has addressed this problem, in which the intravariceal technique
proved superior21. We continue to use a combined intra- and paravariceal tech-
nique, the latter mostly during the initial sclerotherapy sessions to prevent trouble-
some needle puncture bleeds from large variceal channels.
Kitano et al. 22 recently proposed a modified two stage intravariceal and paravari-
ceal technique making use of an overtube. Thrombosis of the varices is first induced
by intravariceal injections, followed by the deliberate promoting of mucosal
ulceration with submucosal injections. This technique has markedly reduced the
incidence of recurrent varices and bleeding in their patients.
The best choice of sclerosant also remains uncertain. The most widely used
agents are ethanolamine oleate and sodium tetradecyl sulfate for intravariceal
injection and polidocanol for paravariceal injections. Again there is a paucity of
controlled trials evaluating the efficacy of these agents. Two studies by one group
have shown ethanolamine oleate to be superior to polidocano123 and to sodium
tetradecyl sulfate
24 while polidocanol was more effective than absolute alcohol
when investigated by another group. On balance it would appear that there is no
clear superior sclerotherapy technique or sclerosing agent when these procedures
are carried out by experts.
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recurrent variceal bleeding, it would seem important to achieve this goal in the
shortest possible time. Three controlled studies have shown that a one week
interval treatment schedule achieves earlier variceal obliteration than when treat-
ments are spaced by two
26 or three27’28 weeks. The incidence of rebleeding,
however, was only significantly reduced in one study
28 and in none of the studies
was there a reduction in mortality. A higher incidence of oesophageal ulceration in
the "one week" regimen delayed treatment in a considerable number of patients
and may explain why this regimen was not unequivocally better than the "three
week" one.
CONCLUSIONS
Repeated sclerotherapy by virtue of its simplicity and safety, has earned a rightful
place in the long-term treatment of patients after variceal bleeding and has become
the treatment of choice in Cape Town. It would now seem to be the preferred
treatment for Child C and most Child B patients who tolerate surgical intervention
poorly. Sclerotherapy does not impair liver function or promote hepatic encephalo-
pathy and therefore makes it a strong contender in the treatment of good risk
patients as well. In patients with extrahepatic portal vein thrombosis, sclerotherapy
has proved to be as good as or even better than devascularization operations.
Recurrent variceal bleeding remains the most limiting aspect of long-term
sclerotherapy. While the risk diminishes with time as the variceal channels are
obliterated, some recurrent bleeds are fatal or contribute to deaths from liver
failure. Defining sclerotherapy failures remains a problem. The number of scleroth-
erapy sessions and the time taken to eradicate varices are not necessarily measures
of success. Many of the patients who require more than the average number of
sclerotherapy sessions ultimately do well and even patients with persistent varices
may not bleed again and succumb from causes other than recurrent variceal
bleeding. We believe that patients who develop life-threatening variceal bleeding
after an adequate course of treatment should be regarded as failures of long-term
treatment and in these an early salvage operation as proposed by Warren et al
9 and
Cello et al.
3 would seem to give the best results.
Our current long-term management policy is to submit patients to a weekly
sclerotherapy session with the aim of early eradication, appreciating that factors
such as the development of injection site ulceration and patient compliance
frequently interfere with the sclerotherapy programme. After eradication of the
varices patients should be followed up at six to 12 month intervals and, if varices
recur, an aggressive sclerotherapy schedule should be instituted again. It is hoped
that in the future the addition of effective pharmacological agents will improve the
results of sclerotherapy both in terms of facilitating earlier eradication and
prevention of recurrence.
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